Biosergen's Rights Issue Oversubscribed
Biotechnology company Biosergen AB announced today the outcome of its rights issue, which closed on August 26, 2026. The issue was oversubscribed.
Biotechnology firm Biosergen AB announced today the final results of its recent rights issue of shares. The subscription period for the offering concluded on August 26, 2026. According to the company's statement, 58,905,204 shares were subscribed for using subscription rights, representing approximately 73.8 percent of the offered shares.
In addition, applications were received to subscribe for 62,693,744 shares without the use of subscription rights. This figure corresponds to approximately 78.5 percent of the shares made available in the offering, indicating a significant oversubscription.
The company stated that the final outcome of the rights issue is being confirmed. Further details regarding the number of subscribed shares and the final subscription level will be disclosed once the company's board of directors has approved the results.